xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

438

KUANetal.

pretreatment plasma Epstein-Barr virus DNA level in a non Chinese population: secondary analysis from a prospective randomized trial. Jpn J Clin Oncol . 2019;49(12):1100-1113. https://doi.org/10.1093/jjco/hyz109 1639. Hui EP, Li WF, Ma BB, et al. Integrating postradiother apy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant ther apy. Ann Oncol . 2020;31(6):769-779. https://doi.org/10.1016/j. annonc.2020.03.289 1640. Li WZ, Wu HJ, Lv SH, et al. Assessment of survival model performance following inclusion of Epstein-Barr virus DNA status in conventional TNM staging groups in Epstein-Barr virus-related nasopharyngeal carcinoma. JAMA Netw Open . 2021;4(9):e2124721. https://doi.org/10.1001/ jamanetworkopen.2021.24721 1641. Twu CW, Wang WY, Chen CC, et al. Metronomic adju vant chemotherapy improves treatment outcome in nasopha ryngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys . 2014;89(1):21-29. https://doi.org/ 10.1016/j.ijrobp.2014.01.052 1642. Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adju vant chemotherapy: a randomized controlled trial. J Clin Oncol . 2018;36(31):3091-3100. https://doi.org/10.1200/jco.2018. 77.7847 1643. Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Can cer Res . 2010;16(3):1016-1024. https://doi.org/10.1158/1078 0432.Ccr-09-2796 1644. Hsu CL, Chang KP, Lin CY, et al. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. HeadNeck . 2012;34(8):1064-1070. https://doi.org/10.1002/hed.21890 1645. Ma B, Hui EP, King A, et al. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluo rodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recur rent nasopharyngeal carcinoma. Br JCancer . 2018;118(8):1051 1055. https://doi.org/10.1038/s41416-018-0026-9 1646. Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal can cer. NEngl JMed . 2017;377(6):513-522. https://doi.org/10.1056/ NEJMoa1701717 1647. Lam WKJ, Jiang P, Chan KCA, et al. Sequencing-based count ing and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci USA . 2018;115(22):E5115-E5124. https://doi. org/10.1073/pnas.1804184115 1648. Lam WKJ, Jiang P, Chan KCA, et al. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus associated diseases. NatCommun . 2019;10(1):3256. https://doi. org/10.1038/s41467-019-11226-5 1649. Wu Q, Wang M, Liu Y, et al. HPV positive status is a favor able prognostic factor in non-nasopharyngeal head and neck squamous cell carcinoma patients: a retrospective study from the surveillance, epidemiology, and end results database.

geal carcinoma in Asian populations. Asian Pac J Cancer Prev . 2012;13(6):2577-2581. https://doi.org/10.7314/apjcp.2012. 13.6.2577 1626. Song C, Yang S. A meta-analysis on the EBV DNA and VCA IgA in diagnosis of Nasopharyngeal Carcinoma. Pak J Med Sci . 2013;29(3):885-890. https://doi.org/10.12669/pjms.293.2907 1627. Sun D, Yang Z, Fu Y, et al. Clinical value of serum Epstein-Barr virus DNA assay in the diagnosis of nasopharyngeal carci noma. Tumour Biol . 2014;35(9):8787-8793. https://doi.org/10. 1007/s13277-014-2148-x 1628. Liu W, Chen G, Gong X, et al. The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis. Cancer Cell Int . 2021;21(1):164. https://doi.org/10.1186/s12935-021-01862-7 1629. Zhang W, Chen Y, Chen L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era? A systematic review and meta-analysis of 7836 cases. Medicine . 2015;94(20):e845. https://doi.org/10. 1097/md.0000000000000845 1630. Zhang J, Shu C, Song Y, Li Q, Huang J, Ma X. Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyn geal carcinoma: a meta-analysis. Medicine . 2016;95(40):e5130. https://doi.org/10.1097/md.0000000000005130 1631. Liu TB, Zheng ZH, Pan J, Pan LL, Chen LH. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal car cinoma: a meta-analysis. Clin Invest Med . 2017;40(1):E1-E12. https://doi.org/10.25011/cim.v40i1.28049 1632. Xie X, Ren Y, Wang K, Yi B. Molecular prognostic value of circulating Epstein-Barr viral DNA in nasopharyngeal carci noma: a meta-analysis of 27,235 cases in the endemic area of Southeast Asia. Genet Test Mol Biomarkers . 2019;23(7):448-459. https://doi.org/10.1089/gtmb.2018.0304 1633. Qu H, Huang Y, Zhao S, Zhou Y, Lv W. Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol . 2020;277(1):9-18. https://doi.org/10.1007/s00405-019-05699-9 1634. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol . 2006;24(34):5414-5418. https://doi. org/10.1200/jco.2006.07.7982 1635. Zhang L, Tang LQ, Chen QY, et al. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyn geal carcinoma in the era of intensity-modulated radiother apy. Oncotarget . 2016;7(5):6221-6230. https://doi.org/10.18632/ oncotarget.6754 1636. Guo R, Tang LL, Mao YP, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopha ryngeal carcinoma. Cancer . 2019;125(1):79-89. https://doi.org/ 10.1002/cncr.31741 1637. Lee VH, Kwong DL, Leung TW, et al. The addition of pre treatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer . 2019;144(7):1713-1722. https://doi.org/10.1002/ijc. 31856 1638. Kitpanit S, Jittapiromsak N, Sriyook A, et al. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with